SRPT Q3 2019 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$99M+26.2% YoY

Gross Profit

$86M86.8% margin

Operating Income

-$124M-124.8% margin

Net Income

-$126M-127.5% margin

EPS (Diluted)

$-1.70

QoQ Revenue Growth

+4.6%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$77M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$707M

Stockholders' Equity

$995M

Cash & Equivalents

$725M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$99M	$78M	+26.2%
Gross Profit	$86M	$70M	+23.3%
Operating Income	-$124M	-$70M	-76.3%
Net Income	-$126M	-$76M	-65.4%